BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours
Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the developme... (Source: Molecular Cancer)
Source: Molecular Cancer - August 30, 2023 Category: Cancer & Oncology Authors: Qin Yu, Wenhao Fu, Yutang Fu, Wenjing Ye, Huiqiong Yan, Zecheng Yu, Ruirui Li, Yili Cai, Yuxin Chen, Lingyun Wang, Xianqiao Wei, Yangkun Chen, Yuheng Zhang, Huazhong Ying, Furong Tang, Fangwei Dai & hellip; Tags: Correspondence Source Type: research
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
(Source: Molecular Cancer)
Source: Molecular Cancer - August 19, 2023 Category: Cancer & Oncology Authors: Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun & hellip; Tags: Correction Source Type: research
Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-related mortality worldwide, with more than half of them occurred in China. Radiotherapy (RT) has been widely used for treatin... (Source: Molecular Cancer)
Source: Molecular Cancer - August 19, 2023 Category: Cancer & Oncology Authors: Lingbo An, Mingyang Li and Qingge Jia Tags: Review Source Type: research
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to... (Source: Molecular Cancer)
Source: Molecular Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Antonino Glaviano, Aaron S. C. Foo, Hiu Y. Lam, Kenneth C. H. Yap, William Jacot, Robert H. Jones, Huiyan Eng, Madhumathy G. Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H. Kulke, Richard D. Baird, Jyothi S. Prabhu, Daniela Carbone, Camilla Pecoraro, D Tags: Review Source Type: research
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors
New therapies are urgently needed in melanoma, particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors. To uncover novel potentiators of T cell anti-tumor immunity, we carri... (Source: Molecular Cancer)
Source: Molecular Cancer - August 15, 2023 Category: Cancer & Oncology Authors: Pawe ł Stachura, Wei Liu, Haifeng C. Xu, Agnès Wlodarczyk, Olivia Stencel, Piyush Pandey, Melina Vogt, Sanil Bhatia, Daniel Picard, Marc Remke, Karl S. Lang, Dieter Häussinger, Bernhard Homey, Philipp A. Lang, Arndt Borkhardt and Aleksandra A. Pandyra Tags: Research Source Type: research
m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism
Glycolytic reprogramming is one of the most important features of cancer and plays an integral role in the progression of cancer. In cancer cells, changes in glucose metabolism meet the needs of self-prolifera... (Source: Molecular Cancer)
Source: Molecular Cancer - August 15, 2023 Category: Cancer & Oncology Authors: Shi-Wei Yue, Hai-Ling Liu, Hong-Fei Su, Chu Luo, Hui-Fang Liang, Bi-Xiang Zhang and Wei Zhang Tags: Review Source Type: research
Correction: Reprogramming anchorage dependency by adherent ‑to‑suspension transition promotes metastatic dissemination
(Source: Molecular Cancer)
Source: Molecular Cancer - August 14, 2023 Category: Cancer & Oncology Authors: Hyunbin D. Huh, Yujin Sub, Jongwook Oh, Ye Eun Kim, Ju Young Lee, Hwa ‑Ryeon Kim, Soyeon Lee, Hannah Lee, Sehyung Pak, Sebastian E. Amos, Danielle Vahala, Jae Hyung Park, Ji Eun Shin, So Yeon Park, Han Sang Kim, Young Hoon Roh & hellip; Tags: Correction Source Type: research
Retraction Note: N6-methyladenosine induced mir-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1
(Source: Molecular Cancer)
Source: Molecular Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Hongsheng Wang, Qianqian Deng, Ziyan Lv, Yuyi Ling, Xue Hou, Zhuojia Chen, Xiaoxiao Dinglin, Shuxiang Ma, Delan Li, Yingmin Wu, Yanxi Peng, Hongbing Huang and Likun Chen Tags: Retraction Note Source Type: research
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway
Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN is one of the mo... (Source: Molecular Cancer)
Source: Molecular Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Jan Pencik, Cecile Philippe, Michaela Schlederer, Emine Atas, Matteo Pecoraro, Sandra Grund-Gr öschke, Wen (Jess) Li, Amanda Tracz, Isabel Heidegger, Sabine Lagger, Karolína Trachtová, Monika Oberhuber, Ellen Heitzer, Osman Aksoy, Heidi A. Neubauer, Be Tags: Research Source Type: research
Correction: CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma
(Source: Molecular Cancer)
Source: Molecular Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Jinpeng Du, Tian Lan, Haotian Liao, Xuping Feng, Xing Chen, Wenwei Liao, Guimin Hou, Lin Xu, Qingbo Feng, Kunlin Xie, Mingheng Liao, Xiangzheng Chen, Jiwei Huang, Kefei Yuan and Yong Zeng Tags: Correction Source Type: research
Protein regulator of cytokinesis 1: a potential oncogenic driver
Protein regulator of cytokinesis 1 (PRC1) is involved in cytokinesis. Growing evidence suggests the association of PRC1 with multiple cancers. Here, we unveil that, in 28 cancer types, PRC1 is higher expressed... (Source: Molecular Cancer)
Source: Molecular Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Sijing Li, Omar Moti ño, Flavia Lambertucci, Isabelle Martins, Li Sun and Guido Kroemer Tags: Correspondence Source Type: research
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial
This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4 (hrBMP4) – an inhibitory regulator of cancer stem ... (Source: Molecular Cancer)
Source: Molecular Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Eelke M. Bos, Elena Binda, Iris S.C. Verploegh, Eva Wembacher, Daphna Hoefnagel, Rutger K. Balvers, Anne L. Korporaal, Andrea Conidi, Esther A. H. Warnert, Nadia Trivieri, Alberto Visioli, Paola Zaccarini, Laura Caiola, Rogier van Wijck, Peter van der Spe Tags: Correspondence Source Type: research
Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis
The reversible oxidation-reduction homeostasis mechanism functions as a specific signal transduction system, eliciting related physiological responses. Disruptions to redox homeostasis can have negative conseq... (Source: Molecular Cancer)
Source: Molecular Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Yuqing Ren, Ruizhi Wang, Siyuan Weng, Hui Xu, Yuyuan Zhang, Shuang Chen, Shutong Liu, Yuhao Ba, Zhaokai Zhou, Peng Luo, Quan Cheng, Qin Dang, Zaoqu Liu and Xinwei Han Tags: Review Source Type: research
Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer
Chimeric antigen receptor (CAR) -T cell therapy is an efficient therapeutic strategy for specific hematologic malignancies. However, positive outcomes of this novel therapy in treating solid tumors are curtail... (Source: Molecular Cancer)
Source: Molecular Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Jian Chen, Tianchuan Zhu, Guanmin Jiang, Qi Zeng, Zhijian Li and Xi Huang Tags: Research Source Type: research
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFR α genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to... (Source: Molecular Cancer)
Source: Molecular Cancer - August 9, 2023 Category: Cancer & Oncology Authors: Javier Martin-Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martinez-Trufero, Giovanni Grignani, Antoine Italiano, Javier Lavernia, Ana Vallejo, Paolo Dei Tos, Francois Le Loarer, Ricardo Gonzalez-Campora, Rafael Ramos, Diana Hern ández-Jo Tags: Correspondence Source Type: research
